Yale researchers find new piece in Alzheimer’s puzzle

	Tweet

Yale researchers have filled in a missing gap on the molecular road map of Alzheimer’s disease.

In the Feb. 26 issue of the journal Nature, the Yale team reports that cellular prion proteins trigger the process by which amyloid-beta peptides block brain function in Alzheimer’s patients.

“It has been a black box,” said Stephen M. Strittmatter, senior author of the study and the Vincent Coates Professor of Neurology and director of Cellular Neuroscience, Neurodegeneration and Repair at the Yale School of Medicine. “We have known that amyloid-beta is bad for the brain, but we have not known exactly how amyloid-beta does bad things to neurons.”

After an extensive gene expression analysis, the first step in amyloid-beta damage appears to involve cellular prion proteins. These proteins are normally harmless and exist within all cells, but on rare occasions they change shape and cause notorious prion diseases such as Creutzfeldt- Jacob disease, or its well-known variant, mad cow disease.

When the Yale team searched hundreds of thousands of candidates for potential disease-mediating receptors for the specific amyloid-beta form known to play a role in the development of Alzheimer’s disease, the most likely candidate was cellular prion proteins. It seems that amyloid-beta peptides latch onto these cellular prion proteins and precipitate the damage in brain cells.

“They start the cascade that make neurons sick” said Strittmatter, a member of the Kavli Institute for Neuroscience.

Since these cellular prion proteins act at an early stage of disease development, the receptors make a promising target for new Alzheimer’s therapies, Strittmatter said.

The study does not suggest that the conversion of cellular prion proteins to an infectious agent occurs in Alzheimer’s disease, Strittmatter noted. However, the Nature paper does suggest that the role of usually harmless cellular prion proteins in common neurodegenerative diseases should be studied more rigorously, he said.

###

Other members of the Yale team included Juha Lauren, David A. Gimbel, Haakon B. Nygaard, and John W. Gilbert.

This work was supported by research grants from the Falk Medical Research Trust and the National Institutes of Health.

Contact: Bill Hathaway

203-432-1322
Yale University

RELATED STORIES:
“Brain Signature” for Cigarette Cravings Identified   Brain gene makes a female develop as a male   Electrical therapy improves walking after stroke   Thinning bones linked to Alzheimer’s risk   Welders show elevated rate of Parkinson symptoms   US blacks in south at greater risk of stroke death   ‘Tis the Season for Being Happy …Or Not the Holiday Blues   Alzheimer’s protein involved in brain protection   Learning a second language—Is it all in your head?   Blood vessel condition tied to MS, with caveats   Brain imaging provides window into consciousness   Depression Increases Risk of Alzheimer’s Disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]